Cell & Gene Therapies in Rheumatology: Therapeutic Analysis

Currently, there are four cell and gene therapies (CGTs) on the market for various rheumatology indications. Currently, all marketed agents are cell therapies approved across Canada and various Asian markets including Japan, South Korea, and India. Of the approved agents, three agents are currently undergoing clinical development in the US. Among the front-runners are Biostar’s JointStem, which is being developed for osteoarthritis (OA) in the US, with its Phase IIb trial anticipated to complete in Q2 2024, and Kolon TissueGene’s tonogenchoncel-L, which is also being developed for OA, with its Phase III trials anticipated to complete in Q3 2024.

According to the analyst’s Sales and Forecast Database, cell therapies will contribute $108 million (12.5%) and gene-modified cell therapies will contribute $759 million (87.5%) of the total sales within the global CGT market in rheumatology by 2029. This growth is attributed to the high number of cell therapy assets (56% of total assets) in the pipeline and increasing interest in rheumatic diseases due to the increasing prevalence and high unmet need, especially as the aging population increases.

Scope

• Overview of cell and gene therapies (CGT) in Rheumatology. The report focuses on the marketed CGT assets addressing rheumatic diseases as well as the top five rheumatic disease indications with the most CGT pipeline assets. Clients will gain insight into the competitive landscape of leading CGT agents in rheumatic diseases including launch date projections, analyst consensus forecasts, likelihood of approval analysis, pricing strategies, and commentary on current and future players.
• The report also includes outlook from three key opinion leaders in the 5EU, US, and Japan, and analyses key challenges and opportunities in the application of CGTs in rheumatic diseases. Additionally, the report includes commentary on the regulatory landscape of CGTs and on the reimbursement environment.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the CGT in Rheumatology market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact rheumatic disease targeting CGT therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.